Redefining scar quality: A synergistic approach with micro-needling and photodynamic therapy using methylene blue as a photosensitizer: a randomized clinical trial

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Hypertrophic and keloid scars are challenging to treat and can cause both aesthetic and functional problems.

Who Took Part

The abstract describes 37 patients taking part.

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

Novel Study Design: a randomized, double-blind clinical trial was conducted on 37 patients with 94 hypertrophic and keloid scars.

Patients were divided into four groups based on scar type and methylene blue concentration.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Methylene blue (non-peptide stack partner).

Each group underwent five treatment sessions, and scars were assessed using the Japan Scar Scale (JSS) and the Patient and Observer Scar Assessment Scale (POSAS).

What Was Measured

PubMed files the paper under topics including Methylene Blue, Photochemotherapy, Photosensitizing Agents, Keloid, Combined Modality Therapy and Cicatrix.

Author keywords: Clinical trial, Hypertrophic scars, Micro-needling, Photodynamic therapy and Photosensitizer.

What This Means in Plain Language

The paper is a randomized and double-blind study of Methylene blue (non-peptide stack partner) in 37 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Photodiagnosis and photodynamic therapy), a journal based in Netherlands.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.